BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

Cancer Research Communications · Published 2026-04-16 · DOI 10.1158/2767-9764.crc-25-0638

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1158/2767-9764.crc-25-0638

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics · Journal of Translational Medicine · 2026 · Cites or is cited by this article
• Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns · Cancer Research Communications · 2026 · Same journal
• Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study · Cancer Research Communications · 2026 · Same journal
• Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling · Cancer Research Communications · 2026 · Same journal
• Transcriptionally Informed Nucleosome Profiling of Circulating Cell-Free DNA Predicts Breast Cancer Recurrence · Cancer Research Communications · 2026 · Same journal
• Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway · Cancer Research Communications · 2026 · Same journal
• Development of Glypican 3–Targeting Antibody–Drug Conjugates for Hepatocellular Carcinoma Therapy · Cancer Research Communications · 2026 · Same journal
• Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis · Cancer Research Communications · 2026 · Same journal
• BRAF Inhibition–Associated Nuclear Remodeling is Linked to Cancer-Associated Fibroblast Activation · Cancer Research Communications · 2026 · Same journal
• Tissue Context Shapes Distinct Premalignant Outcomes in an HPV16 E6/E7-Mutant Pik3ca Transgenic Mouse Model · Cancer Research Communications · 2026 · Same journal